<DOC>
	<DOCNO>NCT00003603</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . Steroids , dexamethasone prednisolone , may help relieve side effect chemotherapy . It yet know regimen chemotherapy plus steroid therapy effective treating patient multiple myeloma . PURPOSE : Randomized phase III trial compare effectiveness two different regimen chemotherapy plus steroid therapy treat patient multiple myeloma recur first time .</brief_summary>
	<brief_title>Chemotherapy Plus Steroid Therapy Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Compare response rate , response duration , survival patient relapse multiple myeloma treatment lomustine , idarubicin , dexamethasone v melphalan prednisolone . OUTLINE : This randomize study . Patients stratify accord prior autologous transplant ( yes v ) . Patients randomize one two treatment arm . - Arm I : Patients receive oral lomustine day 1 , oral idarubicin daily day 1-3 , oral dexamethasone twice day day 1-4 . Treatment repeat every 28 day 6-9 course absence unacceptable toxicity disease progression . - Arm II : Patients receive oral melphalan daily day 1-4 oral prednisolone twice day day 1-4 . Treatment repeat every 28 day 6-9 course absence unacceptable toxicity disease progression . Some patient may receive oral cyclophosphamide every 7 day oral prednisolone alternate day 6 week concurrently chemotherapy either treatment arm . Quality life assess baseline , 3 , 6 , 9 , 12 month , every 6 month thereafter . Patients follow death . PROJECTED ACCRUAL : A total 660 patient accrue study within 5 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma base least two follow : Paraprotein serum and/or urine Greater 10 % plasma cell bone marrow Lytic bone lesion Measurable serum and/or urine paraprotein Progression first second stable plateau phase No nonsecretory myeloma plasma cell leukemia ( great 2,000/mm^3 circulate plasma cell ) No primary refractory disease second later relapse PATIENT CHARACTERISTICS : Age : 18 Performance status : 03 Life expectancy : Not specify Hematopoietic : Neutrophil count least 1,000/mm^3 Platelet count least 75,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) ALT/AST great 2.5 time ULN Renal : Creatinine le 3.4 mg/dL Cardiovascular : No clinically significant cardiac insufficiency No uncontrolled hypertension Other : No uncontrolled diabetes mellitus No recent history peptic ulceration HIV1 HIV2 negative Fertile patient must use effective contraception 6 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy : No prior allogeneic peripheral blood stem cell bone marrow transplantation No plan future autologous transplantation unless sufficient stored stem cell available Prior interferon allow administered maintenance stable plateau phase No concurrent epoetin alfa Chemotherapy : At least 3 month since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : Concurrent radiotherapy pain treat localize tumor allow Surgery : Not specify Other : No prior participation clinical trial unlicensed product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2001</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>